Rating Change
Morgan Stanley reiterated its Overweight rating on Biohaven Ltd. (NYSE:BHVN) on November 03, 2026.
reiterateNYSE:BHVN
Morgan Stanley Reiterates Overweight Rating on Biohaven Ltd. (BHVN)
Morgan Stanley reiterated its Overweight rating on Biohaven Ltd. (NYSE:BHVN) on November 03, 2026.
At publication ·
What changed
Biohaven Ltd. (NYSE:BHVN) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $15.61
- Market capitalization
- $1.2B
At a glance
Key takeaways
- Morgan Stanley maintained an Overweight rating on Biohaven Ltd. (BHVN) on November 3, 2026, with the stock trading at $15.61 and a market cap of $1.2B.
- Among the 10 most recent analyst ratings, 5 are Buy, 4 are Hold, and 1 is Sell, suggesting modest bullish sentiment.
- Analyst ratings are one of many inputs for investment decisions and have mixed predictive power on their own without significant consensus changes.
- Biohaven operates in the healthcare sector and is followed by multiple major analysts including Morgan Stanley, Canaccord Genuity, and RBC Capital.
Market Context
Biohaven Ltd. operates in the Healthcare sector. The stock currently trades at $15.61 with a market capitalization of $1.2B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biohaven Ltd.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Biohaven Ltd.
Among the 10 most recent ratings: 5 Buy, 4 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 03, 2026 | Morgan Stanley | Overweight | N/A |
| Oct 30, 2026 | Canaccord Genuity | Buy | N/A |
| Oct 23, 2026 | RBC Capital | Sector Perform | N/A |
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Sep 08, 2026 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View BHVN Stock Page
Frequently Asked Questions
What does the Overweight rating mean for BHVN?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Biohaven Ltd. (NYSE:BHVN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BHVN forecast page.
Loading related coverage…
